title: Strategies in renal failure and the impact of lipids.
abstract: The main points to note in terms of strategies in renal failure and the impact of lipids are: 1) Timing and typing of dyslipidemia; 2) Occurrence of dyslipidemia in the course of strategies (conservative, dialysis and transplantation); 3) How the strategies can handle the impact of lipids. Analysis of point 1 confirms what a complex profile uremic dyslipidemia presents, involving the type, class, composition and enzyme systems involved in lipid metabolism. In conservative and dialysis, type IV (triglycerides) predominates; in transplantation, type II (cholesterol). Examination of point 2 shows the non obligatory relationship between dyslipidemia and the various strategies of treatment. Lipid abnormalities, type IV or II, occur in 50-60% of patients. Uremic factors for dyslipidemia include: 1) enhanced hepatic stimulation or altered removal in conservative strategies; 2) the same causes plus "specific" promotors in dialysis (dialysis fluid, plasticizer leaching; bioincompatibility, etc.); 3) steroid therapy and other "accessories" in transplantation. A genetic predisposition is very likely present in all patients. Point 3, finally, analyzes the various "supplements" that each strategy requires to cope with the lipid impact. Generic rules (ranging from doing nothing, to diet, drugs, etc.) are of value in all strategies when dyslipidemia occurs. More specific rules include: a) Conservative strategies: appropriate dietetic optimization and modulation (protein-lipid-carbohydrate ratio in terms of calories); b) Dialysis: timing treatment and improving biocompatibility; c) Transplantation: reducing steroids as much as possible.
authors.affiliation: Institute of Nephrology, St. Orsola University Hospital, Bologna, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Bonomini
authors.forename: M P
authors.initials: MP
authors.lastname: Scolari
authors.forename: G
authors.initials: G
authors.lastname: Mosconi
authors.forename: P
authors.initials: P
authors.lastname: Todeschini
authors.forename: G
authors.initials: G
authors.lastname: Cianciolo
authors.forename: S
authors.initials: S
authors.lastname: Stefoni
mesh_terms: D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008055:Lipids / Q000097:blood*; D012307:Risk Factors
chemical_list: D008055:Lipids